As Massachusetts stockpiles mifepristone, Dean Rebouche says the state can also reassure physicians that they won’t be punished for prescribing it: “it’s the state that governs… the lawful practice of medicine” within its borders. Read More

A Texas judge’s opinion ordering the FDA to withdraw mifepristone could open the door to judge and forum shopping by parties who want to restrict access to other drugs as well, says Dean Rachel Rebouche. Read More

A judicial battle over access to medication abortion is “emblematic of the fight to come,” says Dean Rachel Rebouche. Read More

Conflicting judicial opinions over the FDA’s approval of mifepristone underscore the escalating chaos over abortion in the months since SCOTUS overturned Roe v. Wade, says Dean Rachel Rebouche. Read More    

Dean Rebouche and co-author Greer Donley walk through the conflicting judicial opinions about FDA approval of mifepristone and discuss next steps for the FDA and the Biden administration. Read More

Dean Rachel Rebouche notes that contrary to SCOTUS’s stated purpose in Dobbs, a Texas opinion about mifepristone “deprives states of being able to regulate abortion the way they want.” Read More

Dean Rebouche explains what “enforcement discretion” is and how the FDA can use it to ensure continued access to mifepristone. Read More

As the legal battles churn over access to abortion pills, Dean Rachel Rebouche is clear on the bottom line: “Mifepristone is still on the market, mifepristone is still safe. Nothing immediately has changed.” Read More

While nothing has changed yet in the battle over mifepristone, Dean Rebouche notes that if the Fifth Circuit decision is upheld, it could put an end to delivery through the mail. Read More

In Philadelphia, Black people account for 42% of the population but 60% of those in foster care. Prof. Sarah Katz says this oversurveillance of Black families by DHS leads to a climate of mutual distrust. Read More